SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OSTEOTECH (OSTE)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: andy harrison who wrote (67)12/26/1997 7:41:00 PM
From: Michael Paul Langley  Read Replies (1) of 141
 
Probably just a case of price (P/E) getting ahead of itself in the current marketplace environment(high P/E at the beginning of Dec when it peaked at $32.75). Most of the new shorts will probably cover at current prices or lower $20's. I don't believe anything has fundamentally changed with the Company itself. Jim Collins, of Growth Stock Winners, "expects sales of their Grafton product 39 percent per year between now and 2000, with a new putty formulation leading the way accounting for one-third of all Grafton sales. The putty is proving to be a popular filler in the growing market for spinal cages." He recommends purchase of OSTE between $28-34 (Probable really likes OSTE at the current price). Future growth prospects look promising as physician's awarenesss increases to Grafton product and new products (threaded bone dowel) and services are initiated.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News